Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany
· Delayed Price · Currency is EUR | Market Cap | 116.80B |
| Revenue (ttm) | 10.64B |
| Net Income (ttm) | -517.34M |
| Shares Out | n/a |
| EPS (ttm) | -2.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33 |
| Average Volume | 143 |
| Open | 466.90 |
| Previous Close | 467.30 |
| Day's Range | 466.80 - 466.90 |
| 52-Week Range | 353.40 - 489.20 |
| Beta | 0.46 |
| RSI | 50.67 |
| Earnings Date | May 5, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector.
Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-...
Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals
Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBC's “Halftime Report” to explain why he's buying the Pharmaceutical company
Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals
Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBCs Halftime Report to explain why he's buying the Pharmaceutical company
Evercore's "All-Weather" stock list: NRG Energy, Vistra, Vertex, IBM and ASML
The Investment Committee debate Evercore's "All-Weather" stock list and how you should trade these names.
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ: VRTX) has outperformed the market over the past 5 years by 2.37% on an annualized basis producing an average annual return of 19.23%. Currently, Vertex Pharmaceuticals...
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ: VRTX). And retail traders should know. We noticed this today when the trades showed up on publicl...
Stocks beating the stock market's recent Trump slump have this in common
This year's top performer among the S&P 500 has been CVS Health's stock, which had a bad 2024 and is cheap by a key valuation measure.
Final Trades: Netflix, Meta, Vertex, Interactive Brokers and the COWZ
The Investment Committee give you their top stocks to watch for the second half.
Top 3 Health Care Stocks That May Keep You Up At Night In Q1
As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
In January, the Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Journavx, a non-opioid oral pain signal inhibitor for acute pain . This marked the first approva...
Vertex Pharmaceuticals Secures UK Approval for ALYFTREK® in Cystic Fibrosis Treatment
Vertex Pharmaceuticals Secures UK Approval for ALYFTREK® in Cystic Fibrosis Treatment
Vertex Announces UK MHRA Approval of ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK (deutivacaftor/tezacafto...
Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK...
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
Vertex Pharma drops as UnitedHealth offers Tier 3 coverage for new pain medicine
Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with cheaper Tier 1 and 2 drugs. Read more here.
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript)
Insider Sell: Atkinson Edward Morrow III Sells 2,650 Shares of Vertex Pharmaceuticals Inc (VRTX)
Insider Sell: Atkinson Edward Morrow III Sells 2,650 Shares of Vertex Pharmaceuticals Inc (VRTX)
Insider Sell: David Altshuler Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
Insider Sell: David Altshuler Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansio...
Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opini...
Trade Tracker: Rob Sechan sells McDonald's and Vertex, buys Texas Pacific Land, Amgen and NRG
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves.